Print
Email
Print Edition Stories
Monday, July 27, 2009
RXi Pharma licenses RNAi delivery tech from Advirna
By Mass High Tech Staff
MHT's Marc Songini: RI plans launch of cord blood center
Rodney Brown on NECN: Hacking into medical devices
Worcester-based RXi Pharmaceuticals Corp. reports it has exercised its option to an exclusive worldwide license to RNA interference (RNAi) technologies from Advirna LLC.
No financial details of the agreement were disclosed.
According to RXi (Nasdaq: RXII) officials, the technologies licensed from Boulder, Colo.-based Advirna uses four distinct approaches to deliver RNAi-based therapeutics to living tissue, with the main focus on RNAi delivery without the use of a separate delivery vehicle. The Advirna technology has been integrated into RXi’s rxRNA platform to create self-delivering rxRNAs.
Tod Woolf, president and CEO of RXi, said that the ability to create self-delivering RNAi therapeutics “promises to provide significant competitive advantages in efficacy, toxicity, ease of administration and manufacturing costs.”
In April, RXi appointed Ramani Varanasi as its vice president of business development, promoted then CFO Stephen DiPalma to the office of executive vice president of business operations and CFO, and director of discovery research Joanne Kamens to the role of senior director of that department.
Late last year, RXi Pharmaceuticals and UMass Medical School received a cooperative research grant from the Massachusetts Life Sciences Center. The amount was up to $250,000 per year for the next three years.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
